REGULATORY

MHLW Council Recognizes High Medical Need for 4 APIs/5 Products Including Extended-Release Levodopa/Carbidopa Combo

February 17, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A panel of the Ministry of Health, Labor and Welfare (MHLW) agreed on February 15 that a high unmet medical need exists for four active pharmaceutical ingredients (APIs)/five products including an extended-release levodopa/carbidopa combination product for Parkinson’s disease. The MHLW…

To read the full story

Council OKs Public Knowledge-Based Applications for Rituxan, Ovisot
February 17, 2017
MHLW Council Discusses Issue of Development Requests for Drugs with Low NHI Prices, Few Patients
February 17, 2017

REGULATORY

Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…